Janssen Launching Phase 1 Trial Testing VE202 for Potential IBD Treatment

Janssen Launching Phase 1 Trial Testing VE202 for Potential IBD Treatment
Janssen Biotech will conduct a Phase 1 clinical trial in healthy volunteers to test VE202, an investigational oral treatment for inflammatory bowel disease (IBD), Vedanta Biosciences has announced. In 2015, Janssen bought the rights from Vedanta for VE202, an oral live biotherapeutic product (a treatment consisting of living microorganisms) that contains a curated mix of bacteria usually present in healthy individuals. The launch of the study comes with a payment of $12 million from Janssen — a Johnson & Johnson pharmaceutical company — in milestone payments to Vedanta as part of the companies' ongoing collaboration. “To our knowledge, VE202 is the first drug candidate based on a rationally-defined bacterial consortium to enter the clinic for an autoimmune disease. We are pleased to collaborate with Janssen’s team, which has produced several important drugs for people living with IBD,” Bernat Olle, CEO of Vedanta Biosciences, said in a press release.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *